FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Novel Oncology Drugs in Preclinical Development in FRANCE

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OX401

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 27, 2020

            Details:

            The data will showcase the high affinity with PARP that leads to DDR inhibition, metabolic exhaustion and activation of the innate immune response, specifically in tumoral cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABD-3001

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Xerys Funds

            Deal Size: $9.8 million Upfront Cash: Undisclosed

            Deal Type: Funding February 26, 2020

            Details:

            Advanced BioDesign will finalise its preclinical studies and submit a clinical trial authorization to start clinical phase I in AML in early 2021.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OX401

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2020

            Details:

            Onxeo is building a strong preclinical data set for OX401, optimized for both PARP inhibition and STING response as well as bypass resistance., as homologous recombination deficiency requirements.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SKY01

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: French Tech Seed

            Deal Size: $0.8 million Upfront Cash: Undisclosed

            Deal Type: Funding January 20, 2020

            Details:

            These funds will allow the company to accelerate the development of its flagship drug candidate, before launching a new fundraising round that will address clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BMC121

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Biomica

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 13, 2020

            Details:

            This agreement will accelerate the Biomica's Immuno-Oncology program which is currently planned to enter the clinic in 2021 for proof of concept studies.